For those following the health-care sector, there's no doubt that 2013 will be known as the year of the spinoff. However, the year started out with rampant speculation that another big acquisition was in the cards -- private equity firm Warburg Pincus was looking for a liquidity event for eye-care specialist Bausch & Lomb.
The potential price: $10 billion. The potential suitors: Abbott Labs (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Sanofi (NYSE:SNY). Follow along in the video below as Brenton Flynn runs through the likely final result.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.